To test whether inhibiting PMN tumor infiltration or TAN proangiogenic activity can be used as therapy to curb tumor growth, we utilized commercially available small molecule inhibitors Reparixin (a CXCR2 inhibitor) (46–48) and NSC405020 (allosteric MMP14 inhibitor) (45). Here, MMP14 is linked to neoplasm.